Global Information
회사소개 | 문의

블록버스터 종양학 브랜드 시장 규모, 점유율, 동향 분석 : 브랜드별(Opdivo, Revlimid, Zejula), 적응증별(폐암, 림프종, 다발성 골수종), 부문 예측(2018-2027년)

Blockbuster Oncology Brands Market Size, Share & Trends Analysis Report By Brand (Opdivo, Revlimid, Zejula), By Indication (Lung Cancer, Lymphoma, Multiple Myeloma), And Segment Forecasts, 2018 - 2027

리서치사 Grand View Research, Inc.
발행일 2018년 10월 상품 코드 744627
페이지 정보 영문 170 Pages
가격
US $ 5,950 ₩ 6,755,600 Unprintable PDF by E-mail (Single User License)
US $ 7,950 ₩ 9,026,400 PDF by E-mail (5-User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 2명에서 5명까지 이용할 수 있는 라이선스입니다. 편집 및 인쇄는 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 9,950 ₩ 11,297,200 PDF by E-mail (Enterprise License) help
동일기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 편집 및 인쇄는 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



블록버스터 종양학 브랜드 시장 규모, 점유율, 동향 분석 : 브랜드별(Opdivo, Revlimid, Zejula), 적응증별(폐암, 림프종, 다발성 골수종), 부문 예측(2018-2027년) Blockbuster Oncology Brands Market Size, Share & Trends Analysis Report By Brand (Opdivo, Revlimid, Zejula), By Indication (Lung Cancer, Lymphoma, Multiple Myeloma), And Segment Forecasts, 2018 - 2027
발행일 : 2018년 10월 페이지 정보 : 영문 170 Pages

세계의 블록버스터 종양학 브랜드 시장은 향후 연평균 복합 성장률(CAGR) 7.3%로 확대되어 2027년까지 628억 달러에 이를 것으로 예측됩니다. 적응 확대 임상시험 증가와 면역치료로의 전환이 시장 성장 촉진요인 중 하나입니다.

세계의 블록버스터 종양학 브랜드(Blockbuster Oncology Brands) 시장에 대해 조사했으며, 시장 동향과 2027년까지 예측, 부문별 동향, 지역별 동향, 시장 진출기업 개요 등의 정보를 정리했습니다.

제1장 조사 방법과 범위

제2장 주요 요약

제3장 시장 변수, 동향, 범위

  • 시장 세분화

제4장 시장 정의

제5장 업계 전망

  • 비지니스 부문 동향 분석
  • 가격 분석
  • 시장 변동 분석
  • 비지니스 환경 분석 툴

제6장 경쟁 및 벤더 환경

  • 시장 진출기업 분류
  • 전략적 대처와 결과 분석
  • 기업 리스트
  • 기업의 시장 점유율 분석

제7장 규제 및 정치력

  • 규제 환경

제8장 브랜드 비지니스 분석

제9장 적응 비지니스 분석

제10장 지역별 비지니스 분석

  • 동향 분석
    • 북미
    • 유럽
    • 아시아태평양
    • 라틴아메리카
    • 중동 및 아프리카

제11장 기업 개요

  • BRISTOL MYERS SQUIBB
  • MERCK & CO.
  • ROCHE
  • PFIZER
  • ASTRAZENECA
  • TESARO

제12장 파이프라인 분석

  • 주목 치료법
  • 유망한 향후 진출기업
  • 시장 전망
LSH 18.11.22

List of Tables

  • TABLE 1 Global Blockbuster Oncology Brands Market, by region, 2015 - 2027 (USD Million)
  • TABLE 2 Global Blockbuster Oncology Brands Market, by Indications, 2015 - 2027 (USD Million)
  • TABLE 3 Global Blockbuster Oncology Brands Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 4 North America Market, by country, 2015 - 2027 (USD Million)
  • TABLE 5 North America Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 6 North America Market, by Brand, 2015 - 2027 (USD Million)
  • TABLE 7 U.S. Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 8 U.S. Market, by Brand, 2015 - 2027 (USD Million)
  • TABLE 9 Canada Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 10 Canada Market, by Brand, 2015 - 2027 (USD Million)
  • TABLE 11 Europe Market, by country, 2015 - 2027 (USD Million)
  • TABLE 12 Europe Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 13 Europe Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 14 France Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 15 France Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 16 Germany Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 17 Germany Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 18 Italy Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 19 Italy Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 20 Spain Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 21 Spain Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 22 UK Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 23 UK Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 24 Switzerland Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 25 Switzerland Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 26 Denmark Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 27 Denmark Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 28 Poland Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 29 Poland Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 30 APAC Market, by country, 2015 - 2027 (USD Million)
  • TABLE 31 APAC Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 32 APAC Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 33 Hong Kong Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 34 Hong Kong Market, by Brand, 2015 - 2027 (USD Million)
  • TABLE 35 Singapore Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 36 Singapore Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 37 China Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 38 China Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 39 India Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 40 India Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 41 Japan Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 42 Japan Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 43 Indonesia Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 44 Indonesia Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 45 New Zealand Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 46 New Zealand Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 47 Australia Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 48 Australia Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 49 Philippines Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 50 Philippines Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 51 South Korea Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 52 South Korea Market, by Brands, 2015 - 2027 (USD Million))
  • TABLE 53 Latin America Market, by country, 2015 - 2027 (USD Million)
  • TABLE 54 Latin America Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 55 Latin America Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 56 Argentina Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 57 Argentina Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 58 Brazil Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 59 Brazil Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 60 Mexico Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 61 Mexico Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 62 MEA Market, by country, 2015 - 2027 (USD Million)
  • TABLE 63 MEA Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 64 MEA Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 65 Saudi Arabia Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 66 Saudi Arabia Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 67 Turkey Market, by Indication, 2015 - 2027 (USD Million)
  • TABLE 68 Turkey Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 69 Israel Market, by Brands, 2015 - 2027 (USD Million)
  • TABLE 70 Israel Market, by Brands, 2015 - 2027 (USD Million)

List of Figures

  • FIG. 1 Blockbuster oncology brands market snapshot
  • FIG. 2 Blockbuster Oncology brands market segmentation
  • FIG. 3 Blockbuster oncology brands market driver impact
  • FIG. 4 Blockbuster oncology brands market restraintr impact
  • FIG. 5 SWOT Analysis, By Factor (Political & legal Economic and technological)
  • FIG. 6 Porter's Five Forces Analysis
  • FIG. 7 Value Chain Analysis
  • FIG. 8 Blockbuster oncology brands market:brands outlook and key takeaways
  • FIG. 9 Blockbuster oncology brands Market: Brands Movement Analysis
  • FIG. 10 Tagrisso, 2015 - 2027 (USD Million)
  • FIG. 11 Tecentriq, 2015 - 2027 (USD Million)
  • FIG. 12 Tecentriq, 2015 - 2027 (USD Million)
  • FIG. 13 Tecentriq, 2015 - 2027 (USD Million)
  • FIG. 14 Zejula, 2015 - 2027 (USD Million)
  • FIG. 15 Gazyva, 2015 - 2027 (USD Million)
  • FIG. 16 Revlimid, 2015 - 2027 (USD Million)
  • FIG. 17 Darzalex, 2015 - 2027 (USD Million)
  • FIG. 18 Imbruvica, 2015 - 2027 (USD Million)
  • FIG. 19 Opdivo, 2015 - 2027 (USD Million)
  • FIG. 20 Keytruda, 2015 - 2027 (USD Million)
  • FIG. 21 Blockbuster oncology brands market indication outlook and key takeaways
  • FIG. 22 Blockbuster oncology brands Market: Indication Movement Analysis
  • FIG. 23 Lung cancer , 2015 - 2027 (USD Million)
  • FIG. 24 Breast cancer market, 2015 - 2027 (USD Million)
  • FIG. 25 Multiple myeloma market, 2015 - 2027 (USD Million)
  • FIG. 26 lymphoma market, 2015 - 2027 (USD Million)
  • FIG. 27 Blockbuster oncology brandsmarket: regional outlook and key takeaways
  • FIG. 28 CTMS Market: Regional Movement Analysis
  • FIG. 29 North America
  • FIG. 30 North America market estimates and forecast, 2015 - 2027
  • FIG. 31 U.S. Blockbuster Oncology Brands market, 2015 - 2027 (USD Million)
  • FIG. 32 Canada Blockbuster Oncology Brands market, 2015 - 2027 (USD Million)
  • FIG. 33 Europe
  • FIG. 34 Europe market estimates and forecast, 2015 - 2027
  • FIG. 35 Germany market estimates and forecast, 2015 - 2027
  • FIG. 36 U.K. market estimates and forecast, 2015 - 2027
  • FIG. 37 France market estimates and forecast, 2015 - 2027
  • FIG. 38 Italy market estimates and forecast, 2015 - 2027
  • FIG. 39 Spain market estimates and forecast, 2015 - 2027
  • FIG. 40 Denmark market estimates and forecast, 2015 - 2027
  • FIG. 41 Switzerland market estimates and forecast, 2015 - 2027
  • FIG. 42 Poland. market estimates and forecast, 2015 - 2027
  • FIG. 43 Asia-Pacific
  • FIG. 44 Asia-Pacific market estimates and forecast, 2015 - 2027
  • FIG. 45 Japan market estimates and forecast, 2015 - 2027
  • FIG. 46 China. market estimates and forecast, 2015 - 2027
  • FIG. 47 India market estimates and forecast, 2015 - 2027
  • FIG. 48 Thailand market estimates and forecast, 2015 - 2027
  • FIG. 49 Australia market estimates and forecast, 2015 - 2027
  • FIG. 50 Philippines market estimates and forecast, 2015 - 2027
  • FIG. 51 South Korea market estimates and forecast, 2015 - 2027
  • FIG. 52 Indonesia. market estimates and forecast, 2015 - 2027
  • FIG. 53 Hong Kong market estimates and forecast, 2015 - 2027
  • FIG. 54 Singapore. market estimates and forecast, 2015 - 2027
  • FIG. 55 Latin America
  • FIG. 56 Latin America market estimates and forecast, 2015 - 2027
  • FIG. 57 Brazil market estimates and forecast, 2015 - 2027
  • FIG. 58 Mexico market estimates and forecast, 2015 - 2027
  • FIG. 59 Argentina market estimates and forecast, 2015 - 2027
  • FIG. 60 Middle East & Africa
  • FIG. 61 Middle east market estimates and forecast, 2015 - 2027
  • FIG. 62 Suadi Arabia market estimates and forecast, 2015 - 2027
  • FIG. 63 Turkey market estimates and forecast, 2015 - 2027
  • FIG. 64 Israel market estimates and forecast, 2015 - 2027
  • FIG. 65 Company Profile

The global blockbuster oncology brands market is poised to reach USD 62.80 billion by 2027, according to a new report by Grand View Research, Inc., progressing at a CAGR of 7.3% during the forecast period. Shift towards immunotherapies coupled with increasing number of indication expansion trials is one of the primary growth stimulants for the market.

Current market analysis reveals Revlimid and Opdivo as bestselling therapies in the marketplace in 2017. However, a robust pipeline will uplift Opdivo's sales, while Revlimid's patent expiration will lower its revenue share in the market by 2027. Although Keytruda poses strong competition to Opdivo, especially after bagging a frontline approval for NSCLC in 2017, the immunotherapeutic is expected to trail behind the latter by 2027.

Lifecycle management strategies, including expansion of approved indications and development of combination therapies, underline competitive dynamics in the global blockbuster oncology brands market. Collaborative agreements signed by participating companies facilitate development, commercialization, and regional expansion of products. Such strategies not only enable players to gain easy access into new markets, but also allow them to leverage scientific and technological expertise of their collaborative partner.

Further key findings from the report suggest:

  • North America dominated the global arena in 2017, with approximately 65.0% share. The region is likely to maintain its position through 2027
  • In terms of revenue, the lung cancer segment is estimated to expand at a CAGR of over 9.0% during the forecast period
  • The multiple myeloma segment held more than 30.0% of the market revenue in 2017 and is anticipated to lose its position to lung cancer by 2027
  • Europe is projected to experience modest growth during the forecast period due to delays in cost-effectiveness analysis, carried out by health technology assessment bodies, slowing approval process and lowering reimbursement

Some of the key companies present in the market are: Tesaro, Inc.; Merck &Co.; Bristol Myers Squibb; AstraZeneca Plc; and Roche Ltd.

Table of Contents

Chapter 1: Methodology And Scope

  • 1.1 Research Methodology
  • 1.2 Research Scope And Assumptions
  • 1.3 List Of Abbreviations

Chapter 2: Executive Summary

  • 2.1 Market Summary

Chapter 3: Market Variables, Trends & Scope

  • 3.1 Market Segmentation

Chapter 4: Market Definitions

Chapter 5: Industry Outlook

  • 5.1 Business Segment Trend Analysis
  • 5.2 Pricing Analysis
  • 5.3 Market Variable Analysis
    • 5.3.1 Market Drivers Analysis
      • 5.3.1.1 Accelerated Approvals Expedite Market Launch
      • 5.3.1.2 Immuno-Oncology Therapies As First Line Treatment
    • 5.3.2 Market Restraints Analysis
      • 5.3.2.1 High Therapy Costs Hinders Market Access
  • 5.4 Business Environment Analysis Tools
    • 5.4.1 SWOT Analysis; By Factor (POLITICAL & LEGAL, Economic And Technological)
    • 5.4.2 Porter's Five Forces Analysis

Chapter 6: Competitive & Vendor Lanscape

  • 6.1 Market Participation Categorization
    • 6.1.1 Market Leaders
    • 6.1.2 Innovators
  • 6.2 Strategic Initiatives & Outcome Analysis
    • 6.2.1 List Of Key Strategies, By Company
  • 6.4 List Of Key Companies, By Region
  • 6.5 List Of Key Companies, By Indication
  • 6.6 List Of Key Companies, By Brands
  • 6.7 Company Market Share Analysis

Chapter 7: Regulatory And Political Forces

  • 7.1 Regulatory Landscape
    • 7.1.1 North America
    • 7.1.2 Europe
    • 7.1.3 Asia Pacific
    • 7.1.4 Middle East & Africa
    • 7.1.5 Latin America

Chapter 8: Brands Business Analysis

  • 8.1 Blockbuster Oncology Brands Market: Brand Analysis
    • 8.1.1. Tagrisso
      • 8.1.1.1 Tagrisso, By Revenue, 2015 - 2027 (USD Million)
    • 8.1.2 Tecentriq
      • 8.1.2.1 Tecentriq, By Revenue, 2015 - 2027 (USD Million)
    • 8.1.3 Ibrance
      • 8.1.3.1 Ibrance, By Revenue, 2015 - 2027 (USD Million)
    • 8.1.4 Perjeta
      • 8.1.4.1 Perjeta, By Revenue, 2015 - 2027 (USD Million)
    • 8.1.5 Zejula
      • 8.1.5.1 Zejula, By Revenue, 2015 - 2027 (USD Million)
    • 8.1.6 Gazyva
      • 8.1.6.1 Gazyva, By Revenue, 2015 - 2027 (USD Million)
    • 8.1.7 Revlimid
      • 8.1.7.1 Revlimid, By Revenue, 2015 - 2027 (USD Million)
    • 8.1.8 Darzalex
      • 8.1.8.1 Darzalex, By Revenue, 2015 - 2027 (USD Million)
    • 8.1.9 Imbruvica
      • 8.1.9.1 Imbruvica, By Revenue, 2015 - 2027 (USD Million)
    • 8.1.10 Opdivo
      • 8.1.10.1 Opdivo, By Revenue, 2015 - 2027 (USD Million)
    • 8.1.11 Keytruda
      • 8.1.11.1 Keytruda, By Revenue, 2015 - 2027 (USD Million)

Chapter 9: Indications Business Analysis

  • 9.1. Blockbuster Oncolgoy Brands: Indications Movement Analysis
    • 9.1.1. Lung Cancer
      • 9.1.1.1 Lung Cancer Estimates And Forecasts, 2015 - 2027 (USD Million)
    • 9.1.2 Breast Cancer
      • 9.1.2.1 Breast Cancer Estimates And Forecasts, 2015 - 2027 (USD Million)
    • 9.1.3 Multiple Myeloma
      • 9.1.3.1 Multiple Myeloma Estimates And Forecasts, 2015 - 2027 (USD Million)
    • 9.1.4 Lymphoma
      • 9.1.4.1 Lymphoma Estimates And Forecasts, 2015 - 2027 (USD Million)
    • 9.1.5 Others
      • 9.1.5.1 Lymphoma Estimates And Forecasts, 2015 - 2027 (USD Million)

Chapter 10: Regional Business Analysis

  • 10.1. Blockbuster Oncology Brands Market: Regional Movement Analysis
    • 10.1.1. North America
      • 10.1.1.1 North America Market Estimates And Forecast, 2015 - 2027
      • 10.1.1.2 U.S.
      • 10.1.1.2.1 U.S. Blockbuster Oncology Brands Market, 2015 - 2027 (USD Million)
      • 10.1.1.3 Canada
      • 10.1.1.3.1 Canada Blockbuster Oncology Brands Market, 2015 - 2027 (USD Million)
    • 10.1.2. Europe
      • 10.1.2.1 Europe Market Estimates And Forecast, 2015 - 2027
      • 10.1.2.2 Germany
      • 10.1.2.2.1 Germany Market Estimates And Forecast, 2015 - 2027
      • 10.1.2.3 U.K.
      • 10.1.2.3.1 U.K. Market Estimates And Forecast, 2015 - 2027
      • 10.1.2.4 France
      • 10.1.2.4.1 France Market Estimates And Forecast, 2015 - 2027
      • 10.1.2.5 Italy
      • 10.1.2.5.1 Italy Market Estimates And Forecast, 2015 - 2027
      • 10.1.2.6 Spain
      • 10.1.2.6.1 Spain Market Estimates And Forecast, 2015 - 2027
      • 10.1.2.7 Denmark
      • 10.1.2.7.1 Denmark Market Estimates And Forecast, 2015 - 2027
      • 10.1.2.8 Switzerland
      • 10.1.2.8.1 Switzerland Market Estimates And Forecast, 2015 - 2027
      • 10.1.2.9 Poland
      • 10.1.2.9.1 Poland Market Estimates And Forecast, 2015 - 2027
    • 10.1.3 Asia Pacific
      • 10.1.3.1 Asia Pacific Market Estimates And Forecast, 2015 - 2027
      • 10.1.3.2 Japan
      • 10.1.3.2.1 Japan Market Estimates And Forecast, 2015 - 2027
      • 10.1.3.3 China.
      • 10.1.3.3.1 China Market Estimates And Forecast, 2015 - 2027
      • 10.1.3.4 India
      • 10.1.3.4.1 India Market Estimates And Forecast, 2015 - 2027
      • 10.1.3.5 New Zealand
      • 10.1.3.5.1 New Zealand Market Estimates And Forecast, 2015 - 2027
      • 10.1.3.6 Australia
      • 10.1.3.6.1 Australia Market Estimates And Forecast, 2015 - 2027
      • 10.1.3.7 Philippines
      • 10.1.3.7.1 Philippines Market Estimates And Forecast, 2015 - 2027
      • 10.1.3.8 S.Korea
      • 10.1.3.8.1 S.Korea Market Estimates And Forecast, 2015 - 2027
      • 10.1.3.9 Indonesia
      • 10.1.3.9.1 Indonesia Market Estimates And Forecast, 2015 - 2027
      • 10.1.3.10 Hong Kong
      • 10.1.3.10.1 Hong Kong Market Estimates And Forecast, 2015 - 2027
      • 10.1.3.11 Singapore
      • 10.1.3.11.1 Singapore Market Estimates And Forecast, 2015 - 2027
    • 10.1.4 Latin America
      • 10.1.4.1 Latin America Market Estimates And Forecast, 2015 - 2027
      • 10.1.4.2 Brazil
      • 10.1.4.2.1 Brazil Market Estimates And Forecast, 2015 - 2027
      • 10.1.4.3 Mexico
      • 10.1.4.3.1 Mexico Market Estimates And Forecast, 2015 - 2027
      • 10.1.4.4 Argentina
      • 10.1.4.4.1 Argentina Market Estimates And Forecast, 2015 - 2027
    • 10.1.5 Middle-East
      • 10.1.5.1 Middle-East And Africa Market Estimates And Forecast, 2015 - 2027
      • 10.1.5.2 Saudi Arabia
      • 10.1.5.2.1 Saudi Arabia Market Estimates And Forecast, 2015 - 2027
      • 10.1.5.3 Turkey.
      • 10.1.5.3.1 Turkey Market Estimates And Forecast, 2015 - 2027
      • 10.1.5.4 Israel
      • 10.1.5.4.1 Israel Market Estimates And Forecast, 2015 - 2027

Chapter 11: Company Profile

  • 11.1 BRISTOL MYERS SQUIBB
    • 11.1.1 Company overview
    • 11.1.2 Financial performance
    • 11.1.3 Product overview
    • 11.1.4 Regulatory developments
    • 11.1.5 Product pipeline
    • 11.1.6 Business strategies
    • 11.1.7 Swot analysis
  • 11.2 MERCK & CO.
    • 11.2.1 Company overview
    • 11.2.2 Financial performance
    • 11.2.3 Product overview
    • 11.2.4 Regulatory developments
    • 11.2.5 Product pipeline
    • 11.2.6 Business strategies
    • 11.2.7 Swot analysis
  • 11.3 ROCHE
    • 11.3.1 Company overview
    • 11.3.2 Financial performance
    • 11.3.3 Product overview
    • 11.3.4 Product pipeline
    • 11.3.5 Business strategies
    • 11.3.6 Swot analysis
  • 11.4 PFIZER
    • 11.4.1 Company overview
    • 11.4.2 Financial performance
    • 11.4.3 Product overview
    • 11.4.4 Product pipeline
    • 11.4.5 Business strategies
    • 11.4.6 Swot analysis
  • 11.5 ASTRAZENECA
    • 11.5.1 Company overview
    • 11.5.2 Financial performance
    • 11.5.3 Product overview
    • 11.5.4 Product pipeline
    • 11.5.5 Business strategies
    • 11.5.6 swot analysis
  • 11.6 TESARO
    • 11.6.1 Company overview
    • 11.6.2 Financial performance
    • 11.6.3 Product overview
    • 11.6.4 Product pipeline
    • 11.6.5 Business strategies
    • 11.6.6 Swot analysis

Chapter 12: Pipeline Analysis

  • 12.1 Therapies in focus
  • 12.2 Strong future players
  • 12.3 Market outlook
Back to Top
전화 문의
이용안내
 
BCC Research